Treatment options for neuroinflammation: Focus on Huntington’s disease

Huntington’s disease (HD) is rare but fatal inherited neurodegenerative disorder that clinically manifests as chorea, psychiatric disturbances, and progressive functional impairment. The most affected part is cerebral cortex and striatum leads to dysfunction in neurons and eventual cell death ensue. The current treatment options aim to decrease symptoms and slow down the progression of HD. Treatments such as tetrabenazine and deutetrabenazine target motor symptoms by reducing involuntary movements. Additionally, antipsychotic and antidepressant medications are utilised to treat HD's mental and cognitive symptoms. Research has led to the exploration of potential gene-based treatments and RNA interference (RNAi) techniques. Ongoing research into CRISPR-associated protein 9 (CRISPR-Cas9) and other techniques related to gene editing offer hope to eventually find a cure for this crippling illness